ImmunoGen, Inc. Announces Clinical Data Presentations at the 54th ASH Annual Meeting and Exposition
December 03 2012 - 5:30AM
Business Wire
ImmunoGen, Inc. (NASDAQ: IMGN), a
biotechnology company that develops anticancer therapeutics using
its Targeted Antibody Payload (TAP) technology and antibody
expertise, today announced that there will be clinical data
presentations on two compounds that utilize the Company’s TAP
technology at the 54th annual meeting of the American Society
of Hematology (ASH) to be held December 8-11, 2012 in Atlanta,
GA.
“With ten TAP compounds now in clinical testing – and more in
development behind these – we expect an increasing amount of
clinical data to be reported on TAP compounds for the foreseeable
future,” commented Daniel Junius, President and CEO. “At this
year’s annual meeting of ASH, clinical findings will be reported
with both our IMGN901 compound and Biotest’s BT-062 compound. Over
the course of 2013, we expect data presentations with TAP compounds
for the treatment of a number of types of solid tumors as well as
additional data to be reported for hematological malignancies.”
IMGN901 Oral Presentation
- Title:
“Phase I Study of Lorvotuzumab Mertansine (LM, IMGN901) In
Combination with Lenalidomide (Len) and Dexamethasone (Dex) In
Patients with CD56-Positive Relapsed or Relapsed/Refractory
Multiple Myeloma (MM)” (Abstract #728).
- When/where: Dec. 10 at 4:45 pm ET in the Thomas
Murphy Ballroom 2-3 (Session #653).
BT-062 Poster Presentation
- Title:
“BT062, An Antibody-Drug Conjugate Directed Against CD138, Given
Weekly for 3 Weeks in Each 4 Week Cycle: Safety and Further
Evidence of Clinical Activity” (Abstract #4042).
- When/where: Dec. 10 from 6:00-8:00 pm ET in Hall
B1-B2 (Session #653; Poster III).
About IMGN901
IMGN901 is wholly owned by ImmunoGen and consists of the
Company's CD56-targeting lorvotuzumab antibody with its DM1
cancer-cell killing agent attached using one of its engineered
linkers.
IMGN901 is in Phase II testing, in the NORTH trial, for the
first-line treatment of extensive disease small-cell lung cancer
(SCLC). Encouraging findings also have been seen in initial
evaluations of the compound for the treatment of multiple myeloma
and Merkel cell carcinoma (MCC). IMGN901 has been granted orphan
drug designation for SCLC, multiple myeloma and MCC in the US and
Europe.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using
its TAP technology together with the Company’s expertise in
monoclonal antibodies and tumor biology. A TAP compound uses a
tumor-targeting monoclonal antibody to deliver one of ImmunoGen's
purpose-developed cancer-killing agents specifically to tumor
cells. Ten TAP compounds are now in clinical testing, of which
three are wholly owned by the Company. Marketing applications for
trastuzumab emtansine (T-DM1), the most advanced compound using
ImmunoGen's TAP technology, are under review in the US and Europe.
Roche is developing this compound globally under an agreement
between ImmunoGen and Genentech, a member of the Roche Group. More
information about ImmunoGen can be found at www.immunogen.com.
This press release includes forward-looking statements. For
these statements, ImmunoGen claims the protection of the safe
harbor for forward-looking statements provided by the Private
Securities Litigation Reform Act of 1995. It should be noted that
there are risks and uncertainties related to the development of
novel anticancer products, including risks related to preclinical
and clinical studies, their timings and results. A review of these
risks can be found in ImmunoGen’s Annual Report on Form 10-K for
the fiscal year ended June 30, 2012 and other reports filed with
the Securities and Exchange Commission.
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jul 2023 to Jul 2024